Related Experiment Video
Updated: Jan 8, 2026
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Pharmacokinetic and pharmacodynamic modelling of vedolizumab in Crohn's disease using summary level data and its
Koji Kimura1, Atsushi Yoshida2
1Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan.
Objectives:
To optimize vedolizumab therapy for Crohn's disease, this study aimed to construct a pharmacokinetic/pharmacodynamic (PK/PD) model by applying model-based meta-analysis (MBMA) methods to summary-level clinical data (SLD) and to evaluate a model-informed precision dosing (MIPD) approach based on the model.
Methods:
We used the results of previously reported PK analysis. For PD analysis, summary-level Crohn's Disease Activity Index (CDAI) data were extracted from Phase III trials. Following covariate analysis, the final model was fitted using the Markov chain Monte Carlo Bayesian method (four chains; burn-in 10 000; 100 000 sampling) in NONMEM. The final model was leveraged for empirical Bayes estimation in an MIPD case study.
Key Findings:
The posterior estimates of the final model indicated adequate between-chain mixing and acceptable precision ($\hat{R}$<1.01; most achieved bulk and tail effective sample size > 1000 with lowest values of 541 and 820, respectively). In the case study, the MIPD approach based on the final model accurately predicted the time course of the CDAI with minimal.
Conclusion:
PK/PD modelling by applying MBMA methods to SLD is feasible when access to individual patient data (IPD) is restricted. The MIPD approach demonstrated promising predictive accuracy. Future confirmatory studies using IPD are warranted to establish impact on patient outcomes.
More Related Videos
Related Concept Videos
01:20Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
01:14Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...